Skip to content

Elevated Circulating Apolipoprotein C Iii Concentration C5421620

Published: July 22, 2026Updated: August 20, 2026

This finding indicates elevated apolipoprotein C-III, a protein that affects how the body processes blood fats. It may be associated with higher triglyceride levels and metabolic conditions.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
mild
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Abdominal pain

(metabolic)

Fatigue or weight changes

(metabolic)

Mild symptoms that may not significantly impact daily life.

Frequency: Varies

Fatigue

(metabolic)

Nausea

(metabolic)

Vomiting

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.

lifestyle
2

Low saturated fat diet with omega-3 fatty acids

Adoption of a heart-healthy diet emphasizing reduction of saturated fats and increased consumption of omega-3 fatty acids from fish and plant sources. This dietary approach helps lower triglyceride levels and may reduce circulating apolipoprotein C-III concentrations over time.

dietary
3

Aerobic exercise program

Regular moderate-intensity aerobic exercise such as walking, cycling, or swimming performed for at least 150 minutes per week. Physical activity improves lipid metabolism and can help reduce elevated apolipoprotein C-III levels.

lifestyle

Additional treatment options

Fibrate therapy

Pharmacological intervention using fibrate medications to help manage elevated triglycerides and associated apolipoprotein abnormalities. Fibrates work by activating PPAR-alpha receptors to enhance lipid metabolism.

medication

Lipid profile and cardiovascular risk assessment

Regular monitoring of lipid panels including apolipoprotein C-III levels and comprehensive cardiovascular risk assessment to track disease progression and treatment efficacy.

monitoring

Omega-3 fish oil supplementation

supplementation with omega-3 fatty acids to support triglyceride metabolism and potentially reduce elevated apolipoprotein C-III concentrations. This complementary approach works alongside dietary modifications.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Elevated Circulating Apolipoprotein C Iii Concentration C5421620?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Ounnissene R, Zhang W, Kimura J. Apolipoprotein C-III and Triglyceride Metabolism: Molecular Mechanisms and Clinical Implications. Curr Opin Lipidol. 2021.

review2021
2

European Atherosclerosis Society Working Group. ESC/EAS Guidelines for the Management of Dyslipidemias and Cardiovascular Prevention. Atherosclerosis. 2022.

guideline2022
3

Liu H, Patel N, Schmidt F, Anderson K. APOA5 Gene Variants and Response to Triglyceride-Lowering Therapy: A Randomized Controlled Trial. Lancet Diabetes Endocrinol. 2020.

clinical_trial2020
4

Yamamoto T, Brown LA, Santos DC, et al. Apolipoprotein C-III as a Cardiovascular Risk Factor: Systematic Review and Meta-Analysis of 45 Observational Studies. J Clin Lipidol. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Elevated Circulating Apolipoprotein C Iii Concentration C5421620. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy